Status:
COMPLETED
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will a...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Males and Females (not nursing or not pregnant)
- 18-75 years of age
- Diagnosis of moderate to severe psoriasis for at least six months at the time of screening
- Subjects will require wash-out of certain therapies for the treatment of psoriasis but will be allowed to continue on certain topical therapies
Exclusion
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT00399906
Start Date
August 1 2007
End Date
April 1 2009
Last Update
December 7 2015
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Kogarah, New South Wales, Australia, 2217
2
Local Institution
Greenslopes, Queensland, Australia, 4120
3
Local Institution
North Adelaide, South Australia, Australia, 5006
4
Local Institution
Carlton, Victoria, Australia, 3053